First published · Last updated
Serum proteomics and immunophenotyping for response prediction in uHCC patients treated with atezolizumab and bevacizumab: a prospective single-center analysis
Prospective single-center journal article reporting on serum proteomics and immunophenotyping to predict response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Published 2026-08-01 by Georg Thieme Verlag KG.
Categories: science-and-space, public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 6/10
- Geographic reach
- 1/10
- Global importance
- 2/10
- Impact magnitude
- 2/10
- Positivity
- 5/10
- Urgency
- 1/10
Why it matters
The article examines biomarkers aimed at predicting treatment response in uHCC patients receiving atezolizumab plus bevacizumab.

